Skip to main navigation

Overview
Events & Presentations
News Releases
- For Global Media Only
- For U.S. Media Only
Corporate Governance
Stock
Financial & Filings

News Releases
Intended for U.S. Media Only

News Releases

Year

September 3, 2024

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

September 3, 2024

Ascendis Pharma Reports Second Quarter 2024 Financial Results

August 28, 2024

Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024

August 12, 2024

FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults

June 24, 2024

Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCBH 2024

June 4, 2024

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

June 3, 2024

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

May 30, 2024

Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

May 14, 2024

Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism

May 13, 2024

Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

Displaying 11 - 20 of 31

Shareholder Tools

RSS Feeds

Email Alerts

IR Contact

Footer Corporate Menu

TransCon
About us
Pipeline
Patients
Investors & News
Contact Us

Footer Copyrights Menu

Privacy Policy
Terms of Use

Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group

© November 2024 Ascendis Pharma